Tanshinone IIA Reverses Oxaliplatin Resistance In Human Colorectal Cancer Via Inhibition Of ERK/Akt Signaling Pathway

BACKGROUND: Oxaliplatin (OXA)-based chemotherapy is generally used to treat human cancers, whereas OXA resistance is a main obstacle for the treatment of colorectal cancer (CRC). Evidence has shown that tanshinone IIA (Tan IIA) could induce apoptosis in CRC cells. However, the role of combination of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yonggang, Ge, Tingrui, Xiang, Ping, Zhou, Jingyi, Tang, Shumin, Mao, Haibing, Tang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859961/
https://www.ncbi.nlm.nih.gov/pubmed/32009805
http://dx.doi.org/10.2147/OTT.S217914

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6859961/
https://www.ncbi.nlm.nih.gov/pubmed/32009805
http://dx.doi.org/10.2147/OTT.S217914

Ejemplares similares